Therefore, can some TNF-α inhibitors (adalimumab, infliximab and golimumab) and IL-17 inhibitors (secukinumab and ixekizumab) which can be effectively used in the treatment of RA, AS and other diseases also treat COVID-19 and produce new indications? Here, IL17A is linked to rheumatoid arthritis.